---
document_datetime: 2025-12-02 05:59:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/clopidogrel-krka-dd.html
document_name: clopidogrel-krka-dd.html
version: success
processing_time: 0.1225371
conversion_datetime: 2025-12-28 00:42:51.277262
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Clopidogrel Krka d.d. (previously Zopya)

[RSS](/en/individual-human-medicine.xml/65915)

##### Authorised

This medicine is authorised for use in the European Union

clopidogrel Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76456)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Clopidogrel Krka d.d. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Krka d.d.

Expand section

Collapse section

## What is Clopidogrel Krka d.d.?

Clopidogrel Krka d.d. is a medicine that contains the active substance clopidogrel. It is available as pink, round tablets (75 mg).

Clopidogrel Krka d.d. is a 'generic medicine'. This means that Clopidogrel Krka d.d. is similar to a 'reference medicine' already authorised in the European Union (EU) called Plavix.

## What is Clopidogrel Krka d.d. used for?

Clopidogrel Krka d.d. is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries). Clopidogrel Krka d.d. can be given to the following groups of patients:

- patients who have recently had a myocardial infarction (heart attack). Clopidogrel Krka d.d. can be started between a few days and 35 days after the attack;
- patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel Krka d.d. can be started between seven days and six months after the stroke;
- patients with peripheral arterial disease (problems with blood flow in the arteries).

The medicine can only be obtained with a prescription.

## How is Clopidogrel Krka d.d. used?

The standard dose of Clopidogrel Krka d.d. is one 75 mg tablet once a day, taken with or without food.

## How does Clopidogrel Krka d.d. work?

The active substance in Clopidogrel Krka d.d., clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming 'sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

## How has Clopidogrel Krka d.d. been studied?

Because Clopidogrel Krka d.d. is a generic medicine, studies have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Clopidogrel Krka d.d.?

Because Clopidogrel Krka d.d. is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as those of the reference medicine.

## Why has Clopidogrel Krka d.d. been approved?

The CHMP concluded that, in accordance with EU requirements, Clopidogrel Krka d.d. has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the CHMP's view was that, as for Plavix, the benefit outweighs the identified risk. The Committee recommended that Clopidogrel Krka d.d. be given marketing authorisation.

## Other information about Clopidogrel Krka d.d.

The European Commission granted a marketing authorisation valid throughout the EU for Zopya on 21 September 2009. The name of the medicine was changed to Clopidogrel Krka d.d. on 18 May 2011.

For more information about treatment with Clopidogrel Krka d.d., read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Clopidogrel Krka d.d. : EPAR - Summary for the public

English (EN) (61.71 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 23/01/2012

[View](/en/documents/overview/clopidogrel-krka-dd-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-304)

български (BG) (97.52 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/bg/documents/overview/clopidogrel-krka-dd-epar-summary-public_bg.pdf)

español (ES) (123.97 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/es/documents/overview/clopidogrel-krka-dd-epar-summary-public_es.pdf)

čeština (CS) (147.94 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/cs/documents/overview/clopidogrel-krka-dd-epar-summary-public_cs.pdf)

dansk (DA) (121.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/da/documents/overview/clopidogrel-krka-dd-epar-summary-public_da.pdf)

Deutsch (DE) (64.47 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/de/documents/overview/clopidogrel-krka-dd-epar-summary-public_de.pdf)

eesti keel (ET) (61.73 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/et/documents/overview/clopidogrel-krka-dd-epar-summary-public_et.pdf)

ελληνικά (EL) (160.91 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/el/documents/overview/clopidogrel-krka-dd-epar-summary-public_el.pdf)

français (FR) (64.12 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/fr/documents/overview/clopidogrel-krka-dd-epar-summary-public_fr.pdf)

italiano (IT) (137.63 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/it/documents/overview/clopidogrel-krka-dd-epar-summary-public_it.pdf)

latviešu valoda (LV) (163.03 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/lv/documents/overview/clopidogrel-krka-dd-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (86.17 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/lt/documents/overview/clopidogrel-krka-dd-epar-summary-public_lt.pdf)

magyar (HU) (83.65 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/hu/documents/overview/clopidogrel-krka-dd-epar-summary-public_hu.pdf)

Malti (MT) (147.88 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/mt/documents/overview/clopidogrel-krka-dd-epar-summary-public_mt.pdf)

Nederlands (NL) (123.9 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/nl/documents/overview/clopidogrel-krka-dd-epar-summary-public_nl.pdf)

polski (PL) (149.58 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/pl/documents/overview/clopidogrel-krka-dd-epar-summary-public_pl.pdf)

português (PT) (123.7 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/pt/documents/overview/clopidogrel-krka-dd-epar-summary-public_pt.pdf)

română (RO) (141.39 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/ro/documents/overview/clopidogrel-krka-dd-epar-summary-public_ro.pdf)

slovenčina (SK) (146.3 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sk/documents/overview/clopidogrel-krka-dd-epar-summary-public_sk.pdf)

slovenščina (SL) (142.73 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sl/documents/overview/clopidogrel-krka-dd-epar-summary-public_sl.pdf)

Suomi (FI) (122.32 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/fi/documents/overview/clopidogrel-krka-dd-epar-summary-public_fi.pdf)

svenska (SV) (122.25 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sv/documents/overview/clopidogrel-krka-dd-epar-summary-public_sv.pdf)

## Product information

Clopidogrel Krka d.d. : EPAR - Product Information

English (EN) (262.2 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 13/05/2025

[View](/en/documents/product-information/clopidogrel-krka-dd-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-124)

български (BG) (318.04 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/bg/documents/product-information/clopidogrel-krka-dd-epar-product-information_bg.pdf)

español (ES) (276.26 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/es/documents/product-information/clopidogrel-krka-dd-epar-product-information_es.pdf)

čeština (CS) (281.61 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/cs/documents/product-information/clopidogrel-krka-dd-epar-product-information_cs.pdf)

dansk (DA) (283.55 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/da/documents/product-information/clopidogrel-krka-dd-epar-product-information_da.pdf)

Deutsch (DE) (286.12 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/de/documents/product-information/clopidogrel-krka-dd-epar-product-information_de.pdf)

eesti keel (ET) (257.53 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/et/documents/product-information/clopidogrel-krka-dd-epar-product-information_et.pdf)

ελληνικά (EL) (314.82 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/el/documents/product-information/clopidogrel-krka-dd-epar-product-information_el.pdf)

français (FR) (296.44 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/fr/documents/product-information/clopidogrel-krka-dd-epar-product-information_fr.pdf)

hrvatski (HR) (264.62 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/hr/documents/product-information/clopidogrel-krka-dd-epar-product-information_hr.pdf)

íslenska (IS) (281.46 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/is/documents/product-information/clopidogrel-krka-dd-epar-product-information_is.pdf)

italiano (IT) (271.25 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/it/documents/product-information/clopidogrel-krka-dd-epar-product-information_it.pdf)

latviešu valoda (LV) (262.39 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/lv/documents/product-information/clopidogrel-krka-dd-epar-product-information_lv.pdf)

lietuvių kalba (LT) (287.39 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/lt/documents/product-information/clopidogrel-krka-dd-epar-product-information_lt.pdf)

magyar (HU) (292.97 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/hu/documents/product-information/clopidogrel-krka-dd-epar-product-information_hu.pdf)

Malti (MT) (361.32 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/mt/documents/product-information/clopidogrel-krka-dd-epar-product-information_mt.pdf)

Nederlands (NL) (268.7 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/nl/documents/product-information/clopidogrel-krka-dd-epar-product-information_nl.pdf)

norsk (NO) (276.01 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/no/documents/product-information/clopidogrel-krka-dd-epar-product-information_no.pdf)

polski (PL) (286.43 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/pl/documents/product-information/clopidogrel-krka-dd-epar-product-information_pl.pdf)

português (PT) (269.99 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/pt/documents/product-information/clopidogrel-krka-dd-epar-product-information_pt.pdf)

română (RO) (280.39 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/ro/documents/product-information/clopidogrel-krka-dd-epar-product-information_ro.pdf)

slovenčina (SK) (275.76 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/sk/documents/product-information/clopidogrel-krka-dd-epar-product-information_sk.pdf)

slovenščina (SL) (281.56 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/sl/documents/product-information/clopidogrel-krka-dd-epar-product-information_sl.pdf)

Suomi (FI) (270.47 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/fi/documents/product-information/clopidogrel-krka-dd-epar-product-information_fi.pdf)

svenska (SV) (279.43 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

13/05/2025

[View](/sv/documents/product-information/clopidogrel-krka-dd-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000267861 13/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Clopidogrel Krka d.d. : EPAR - All Authorised presentations

English (EN) (55.1 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 23/01/2012

[View](/en/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-977)

български (BG) (57.41 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/bg/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_bg.pdf)

español (ES) (55.1 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/es/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_es.pdf)

čeština (CS) (55.65 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/cs/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (55.77 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/da/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.75 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/de/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (55.25 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/et/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (54.97 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/el/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_el.pdf)

français (FR) (56.18 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/fr/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (57 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/is/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_is.pdf)

italiano (IT) (54.66 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/it/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (55.41 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/lv/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (56.5 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/lt/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (56.82 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/hu/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (56.75 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/mt/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (54.86 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/nl/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (54.66 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/no/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.54 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/pl/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.78 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/pt/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.47 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/ro/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (56.36 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sk/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.36 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sl/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.12 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/fi/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (54.63 KB - PDF)

**First published:**

14/10/2009

**Last updated:**

23/01/2012

[View](/sv/documents/all-authorised-presentations/clopidogrel-krka-dd-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Clopidogrel Krka d.d. (previously Zopya) Active substance clopidogrel (as hydrochloride) International non-proprietary name (INN) or common name clopidogrel Therapeutic area (MeSH)

- Peripheral Vascular Diseases
- Stroke
- Myocardial Infarction

Anatomical therapeutic chemical (ATC) code B01AC03

### Therapeutic indication

**Secondary prevention of atherothrombotic events**

Clopidogrel is indicated in:

- Adult patients suffering from myocardial infarction (from a few days until less than 35days), ischaemic stroke (from 7days until less than 6months) or established peripheral arterial disease.
- Adult patients suffering from acute coronary syndrome:
- Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
- ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

**Prevention of atherothrombotic and thromboembolic events in atrial fibrillation**

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

## Authorisation details

EMA product number EMEA/H/C/001137

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder Norpharm Regulatory Services Ltd Marketing authorisation issued 20/09/2009 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Clopidogrel Krka d.d.: EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.17 KB - PDF)

**First published:** 13/05/2025

[View](/en/documents/procedural-steps-after/clopidogrel-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Clopidogrel Krka d.d.: EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (200.74 KB - PDF)

**First published:** 25/03/2010

**Last updated:** 13/05/2025

[View](/en/documents/procedural-steps-after/clopidogrel-krka-dd-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Zopya : EPAR - Public assessment report

English (EN) (256.29 KB - PDF)

**First published:** 14/10/2009

**Last updated:** 14/10/2009

[View](/en/documents/assessment-report/zopya-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use  summary of positive opinion  for Zopya

English (EN) (33.14 KB - PDF)

**First published:** 24/06/2009

**Last updated:** 24/06/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-zopya_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Clopidogrel Krka d.d. : EPAR - Product information - tracked changes

English (EN) (82.89 KB - DOCX)

**First published:** 13/05/2025

[View](/en/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_en.docx)

[Other languages (23)](#file-language-dropdown-967)

български (BG) (103.91 KB - DOCX)

**First published:**

13/05/2025

[View](/bg/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_bg.docx)

español (ES) (86.88 KB - DOCX)

**First published:**

13/05/2025

[View](/es/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_es.docx)

čeština (CS) (92.37 KB - DOCX)

**First published:**

13/05/2025

[View](/cs/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (87.31 KB - DOCX)

**First published:**

13/05/2025

[View](/da/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (92.97 KB - DOCX)

**First published:**

13/05/2025

[View](/de/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_de.docx)

ελληνικά (EL) (123.28 KB - DOCX)

**First published:**

13/05/2025

[View](/el/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_el.docx)

français (FR) (94.52 KB - DOCX)

**First published:**

13/05/2025

[View](/fr/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (104.55 KB - DOCX)

**First published:**

13/05/2025

[View](/hr/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (93.08 KB - DOCX)

**First published:**

13/05/2025

[View](/is/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_is.docx)

italiano (IT) (92.46 KB - DOCX)

**First published:**

13/05/2025

[View](/it/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (89.31 KB - DOCX)

**First published:**

13/05/2025

[View](/lv/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (90.47 KB - DOCX)

**First published:**

13/05/2025

[View](/lt/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (90.56 KB - DOCX)

**First published:**

13/05/2025

[View](/hu/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (99.55 KB - DOCX)

**First published:**

13/05/2025

[View](/mt/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (98.26 KB - DOCX)

**First published:**

13/05/2025

[View](/nl/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (87.27 KB - DOCX)

**First published:**

13/05/2025

[View](/no/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_no.docx)

polski (PL) (96.75 KB - DOCX)

**First published:**

13/05/2025

[View](/pl/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_pl.docx)

português (PT) (86.41 KB - DOCX)

**First published:**

13/05/2025

[View](/pt/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_pt.docx)

română (RO) (92.4 KB - DOCX)

**First published:**

13/05/2025

[View](/ro/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (95.54 KB - DOCX)

**First published:**

13/05/2025

[View](/sk/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (89.21 KB - DOCX)

**First published:**

13/05/2025

[View](/sl/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (90.34 KB - DOCX)

**First published:**

13/05/2025

[View](/fi/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (89.78 KB - DOCX)

**First published:**

13/05/2025

[View](/sv/documents/product-information-tracked-changes/clopidogrel-krka-dd-epar-product-information-tracked-changes_sv.docx)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/05/2025

## Share this page

[Back to top](#main-content)